Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses

Treating hemophilia A or B patients with inhibitors is particularly challenging, as they do not respond to replacement therapy with factor VIII or factor IX concentrates. A room temperature–stable formulation of recombinant activated factor VII (rFVIIa; NovoSeven (®) ), which provides improved conve...

Descripción completa

Detalles Bibliográficos
Autores principales: Demartis, Francesco, Batorova, Angelika, Chambost, Hervé, Eshghi, Peyman, Karimi, Mehran, Kavakli, Kaan, El Fegoun, Soraya Benchikh, Cepo, Katarina, Vestergaard, Lene Sommer, Benson, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524848/
https://www.ncbi.nlm.nih.gov/pubmed/31249918
http://dx.doi.org/10.1055/s-0037-1608943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524848/
https://www.ncbi.nlm.nih.gov/pubmed/31249918
http://dx.doi.org/10.1055/s-0037-1608943

Ejemplares similares